References
- Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, Sabracos L, Koussoulas V, Mouktaroudi M, et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004;48:93–9.
- Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002;49:745–55.
- Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2003;34:1084–93.
- Frendeus B, Godaly G, Hang L, Karpman D, Lundstedt AC, Svanborg C. Interleukin 8 receptor deficiency confers susceptibility to acute experimental pyelonephritis and may have a human counterpart. J Exp Med 2000;192:881–90.
- Robaux MA, Dube L, Caillon J, Bugnon D, Kergueris MF, Navas D, et al. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. J Anti- microb Chemother 2001;47:617–22.
- Engelhard D, Pomernz S, Gallily S, Strauss N, Tuomanen E. Serotype-related differences in inflammatory response to Streptococcus pneumoniae in experimental meningitis. J Infect Dis 1997;175:979–82.
- Muzio G, Salvo RA, Trombetta A, Autelli R, Maggiora M, Terreno M, et al. Dose-dependent inhibition of cell proliferation induced by lipid peroxidation products in rat hepatoma cells after enrichment with arachidonic acid. Lipids 1999;34:705–11.
- Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, Giamarellou H. In vitro activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998;58:283–7.
- Arndt P, Abraham E. Immunological therapies for sepsis. Intensive Care Med 2001;27(Suppl 1): S104–15.
- Hubelang MS, Sarma J, McGuire SR, Lu KT, Guo RF, Padgaonkar VA, et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 2001;15:568–70.
- Hinshaw LB, Archer LT, Beller-Todd BK, Benjamin B, Flournoy DJ, Passey R. Survival of primates in lethal septic shock following delayed treatment with steroid. Circ Shock 1981;8:291–300.
- Motoyama T, Okamoto K, Kukita I, Hamaguchi M, Kinoshita Y, Ogawa H. Possible role of increased oxidant stress in multiple organ failure after systemic inflammatory response. Crit Care Med 2003;31:1048–52.
- Hotchkiss RS, tinsley KW, Karl IE. Role of apoptotic cell death in sepsis. Scand J Infect Dis 2003;35:585–93.
- Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001;429:209–29.
- Ianaro A, Ialenti A, Maffia P, Suatebin L, Rompola L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exper Toxicol 2000;292:156–63.
- Yamaryo T, Oishi K, Yoshimine H, Tsuchihashi Y, Matsushima K, Nagatake T. 14-member macrolide promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob Agents Chemother 2003;47:48–53.